# An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells

> **NCT01753453** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 23 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Plerixafor
- **DRUG:** Granulocyte-colony stimulating factor (G-CSF)

## Key facts

- **NCT ID:** NCT01753453
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2021-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01753453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01753453, "An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01753453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*